GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESALF) » Definitions » Cyclically Adjusted Price-to-FCF

ESALF (Eisai Co) Cyclically Adjusted Price-to-FCF : 5.39 (As of Jun. 03, 2025)


View and export this data going back to . Start your Free Trial

What is Eisai Co Cyclically Adjusted Price-to-FCF?

As of today (2025-06-03), Eisai Co's current share price is $27.50. Eisai Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $5.10. Eisai Co's Cyclically Adjusted Price-to-FCF for today is 5.39.

The historical rank and industry rank for Eisai Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ESALF' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 4.77   Med: 8.18   Max: 14.6
Current: 5.57

During the past years, Eisai Co's highest Cyclically Adjusted Price-to-FCF was 14.60. The lowest was 4.77. And the median was 8.18.

ESALF's Cyclically Adjusted Price-to-FCF is ranked better than
95.09% of 326 companies
in the Drug Manufacturers industry
Industry Median: 31.13 vs ESALF: 5.57

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eisai Co's adjusted free cash flow per share data for the three months ended in Mar. 2025 was $0.432. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $5.10 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eisai Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eisai Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Cyclically Adjusted Price-to-FCF Chart

Eisai Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.97 6.52 8.95 7.73 5.57

Eisai Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.73 8.26 6.93 5.52 5.57

Competitive Comparison of Eisai Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eisai Co's Cyclically Adjusted Price-to-FCF falls into.


;
;

Eisai Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eisai Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=27.50/5.10
=5.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Eisai Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.432/111.1000*111.1000
=0.432

Current CPI (Mar. 2025) = 111.1000.

Eisai Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -1.182 98.400 -1.335
201509 2.394 98.500 2.700
201512 1.854 98.100 2.100
201603 3.617 97.900 4.105
201606 -0.979 98.100 -1.109
201609 3.919 98.000 4.443
201612 1.456 98.400 1.644
201703 2.790 98.100 3.160
201706 -1.674 98.500 -1.888
201709 1.534 98.800 1.725
201712 2.569 99.400 2.871
201803 13.883 99.200 15.548
201806 0.862 99.200 0.965
201809 4.291 99.900 4.772
201812 0.572 99.700 0.637
201903 3.791 99.700 4.224
201906 -3.947 99.800 -4.394
201909 1.040 100.100 1.154
201912 1.790 100.500 1.979
202003 7.913 100.300 8.765
202006 -0.263 99.900 -0.292
202009 0.527 99.900 0.586
202012 -1.443 99.300 -1.614
202103 5.709 99.900 6.349
202106 -0.923 99.500 -1.031
202109 9.576 100.100 10.628
202112 -0.178 100.100 -0.198
202203 1.073 101.100 1.179
202206 -0.311 101.800 -0.339
202209 -0.672 103.100 -0.724
202212 -0.363 104.100 -0.387
202303 0.451 104.400 0.480
202306 0.101 105.200 0.107
202309 0.313 106.200 0.327
202312 0.026 106.800 0.027
202403 0.297 107.200 0.308
202406 -0.292 108.200 -0.300
202409 0.161 108.900 0.164
202412 -0.102 110.700 -0.102
202503 0.432 111.100 0.432

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eisai Co  (OTCPK:ESALF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eisai Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eisai Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co Business Description

Industry
Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.